Liverpool School of Tropical Medicine, University of Liverpool, Pembroke Place L35QA Liverpool, UK.
Malar J. 2009 Dec 29;8:310. doi: 10.1186/1475-2875-8-310.
Information on the burden of malaria in early infancy is scarce. Young infants are relatively protected against clinical malaria during the first six months of life due to the presence of maternal antibodies and foetal haemoglobin, and have received relatively little attention with respect to research and treatment guidelines. The World Health Organization provides treatment guidelines for children from six months onwards, without specific treatment guidelines for the younger infants. A number of recent reports however suggest that the burden in this young age group may be underestimated.
A retrospective review of paediatric hospital records at the Queen Elizabeth Central Hospital in Blantyre from 1998 to 2008 from three data sources was carried out. The number of admitted infants < 6 months and < or = 15 years was obtained from the registry books of the Paediatric-Nursery-Department and the Malaria Research Laboratory. For the period 2001-2004, more detailed malaria related admission information was available as part of an ongoing study on severe malaria, allowing a calculation of the proportion of infants < 6 months of age among admissions in children < 5 years.
Retrospective analysis of hospital records showed that over the course of these years, the average annual proportion of paediatric admissions in children < or = 15 years with confirmed malaria aged < 6 months was 4.8% and ranged between 2.8%-6.7%. This proportion was stable throughout the seasons. Between 2001-2004, 9.9% of admissions with confirmed malaria in children < 5 years occurred in infants < 6 months, with numbers increasing steadily during the first six months of life.
These findings are consistent with recent reports suggesting that the burden of malaria during the six first months of life may be substantial, and highlight that more research is needed on dose-optimization, safety and efficacy of anti-malarials that are currently used off-label in this vulnerable patient group.
关于婴儿早期疟疾负担的信息很少。由于母体抗体和胎儿血红蛋白的存在,6 个月龄以下的婴儿在生命的前 6 个月内相对免受临床疟疾的影响,因此在研究和治疗指南方面得到的关注相对较少。世界卫生组织为 6 个月以上的儿童提供了治疗指南,而没有针对年龄较小婴儿的具体治疗指南。然而,最近有许多报告表明,该年龄组的负担可能被低估。
对 1998 年至 2008 年期间在 Blantyre 的伊丽莎白女王中央医院从三个数据源进行了儿科住院病历的回顾性审查。从儿科新生儿病房登记册和疟疾研究实验室获得了 6 个月以下和 15 岁以下的入院婴儿数量。对于 2001-2004 年期间,作为严重疟疾正在进行的研究的一部分,有更详细的疟疾相关入院信息,可计算出 5 岁以下儿童中 6 个月以下婴儿的入院比例。
对住院记录的回顾性分析显示,在这些年中,每年有<6 个月龄且确诊为疟疾的 15 岁以下儿童入院的比例为 4.8%,范围为 2.8%-6.7%。这一比例在整个季节保持稳定。2001-2004 年期间,5 岁以下确诊疟疾患儿中有 9.9%的患儿为 6 个月以下的婴儿,数量在生命的前 6 个月中稳步增加。
这些发现与最近的报告一致,表明生命的头 6 个月内疟疾负担可能很大,这突出表明需要对目前在这一脆弱患者群体中标签外使用的抗疟药物进行剂量优化、安全性和疗效的更多研究。